DEF: Neurocrine Biosciences Announces Annual Meeting and Proxy Statement Details

Neurocrine Biosciences sets date for annual stockholder meeting on May 21, 2025, outlining key proposals including director elections and equity incentive plans.

Summary

• Neurocrine Biosciences will hold its 2025 Annual Meeting of Stockholders on May 21, 2025, at its San Diego corporate offices.
• Stockholders of record as of March 24, 2025, are eligible to vote.
• Key proposals include the election of four Class II directors, an advisory vote on executive compensation, approval of the 2025 Equity Incentive Plan, approval of an amendment to the 2018 Employee Stock Purchase Plan, and ratification of Ernst & Young LLP as the independent accounting firm.
• The Board of Directors recommends voting in favor of all proposals.
• The company has retained Alliance Advisors, LLC, at an approximate cost of $30,000 to assist in soliciting proxies.
• BlackRock, Inc. beneficially owns 13,647,679 shares of common stock, representing 13.8% of the company.
• The Vanguard Group beneficially owns 10,129,687 shares of common stock, representing 10.2% of the company.
• The aggregate number of shares of common stock that may be issued under the 2025 Plan will not exceed (A) the sum of (i) 7,800,000 new shares and (ii) the Prior Plans Returning Shares, as such shares become available from time to time, minus (B) one share for each share of our common stock subject to an appreciation award granted under the 2020 Plan after the Record Date but prior to the date of the Annual Meeting and 2.43 shares for each share of our common stock subject to a full value award granted under the 2020 Plan after the Record Date and prior to the date of the Annual Meeting.
• The maximum number of shares of common stock that may be issued under the Amended ESPP is 1,700,000 shares.
• Ernst & Young LLP billed the company $2,329,291 in 2024 and $2,254,242 in 2023 for audit and tax services.

Sentiment

Score: 7

Explanation: The document is primarily factual and informative, outlining the agenda and proposals for the annual meeting. The positive business highlights and strong stockholder support for executive compensation contribute to a moderately positive sentiment.

Positives

• The Board is committed to strong corporate governance practices.
• The company has a director resignation policy, an overboarding policy, and a clawback policy.
• The company is committed to corporate responsibility, including environmental matters.
• The company has a robust risk management process.
• The company has a comprehensive leadership development and succession planning process.
• The company has a history of high approval rates for its executive compensation program.
• The company has a strong commitment to stockholder engagement.
• The company has a diverse board of directors.
• The company has a strong commitment to ethics and compliance.
• The company has a strong commitment to patient advocacy.

Risks

• The company's success is dependent on scientific and technical advances.
• The company's compensation policies and practices could create risks that are reasonably likely to have a material adverse effect on the company.
• The company's ability to realize the benefit of any tax deductions depends on the company's generation of taxable income.
• The company's ability to attract, retain and motivate its employees, directors and consultants is subject to strong competition.
• The company's business is subject to a variety of risks, including financial risk, legal/compliance risk, scientific/clinical development risk, cybersecurity risk management, and strategic risk.

Future Outlook

The company is focused on discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.

Industry Context

The document provides insight into the corporate governance, executive compensation, and equity incentive practices of a neuroscience-focused biopharmaceutical company, which is valuable for understanding industry standards and trends.

Comparison to Industry Standards

• The document references peer group companies used for compensation benchmarking, including ACADIA Pharmaceuticals, Alkermes plc, Alnylam Pharmaceuticals, Inc., argenx SE, BeiGene, Ltd., BioMarin Pharmaceuticals, Inc., Exelixis, Inc., Horizon Therapeutics plc, Incyte Corporation, Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Karuna Therapeutics, Inc., Organon & Co., Sarepta Therapeutics, Inc., Ultragenyx Pharmaceutical Inc and United Therapeutics Corporation.
• The document mentions that the company's compensation policies and practices are consistent with industry practices for similar biopharmaceutical companies.
• The document mentions that the company's compensation policies and practices do not create risks that are reasonably likely to have a material adverse effect on the company.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
• Employees are eligible to participate in the Employee Stock Purchase Plan.
• The company's success will benefit patients with neurological, neuroendocrine, and neuropsychiatric disorders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will file a Form 8-K with the SEC to announce the final voting results of the Annual Meeting.

Key Dates

Keywords

Neurocrine Biosciences, Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Executive Compensation, Equity Incentive Plan, Employee Stock Purchase Plan, Ernst & Young, Directors, Corporate Governance, Compensation Committee, Audit Committee, BlackRock, Vanguard, INGREZZA, CRENESSITY, Pharmaceuticals, Biotechnology